Carter-Wallace's nasal spray for seasonal allergic rhinitis, Astelin (azelastine), has been recommended for approval in the USA, but only as a twice-daily treatment. The company had sought to get backing for once-daily administration of the antihistamine, but the panel decided that the data did not show efficacy at that dose. In the spring of 1994, the company received a non-approvable letter from the Food and Drug Administration for the product.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze